BioSpace News Archive

Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, will share a poster detailing new data regarding the Company’s IDgenetix® test at the upcoming Psych Congress 2023 conference, being held in Nashville, Tennessee, Sept. 6-10.

Nimbus Therapeutics, LLC announced the closing of a $210 million private financing to advance its next wave of tech-enabled small molecule medicines.

Foundation Medicine Inc., announced the launch of the research use and investigational use versions of FoundationOne®RNA, its broad tissue-based RNA test.

GlycoMimetics, Inc. announced dosing of the first cohort of healthy volunteers in a Phase 1a study of GMI-1687 to evaluate safety, tolerability, and pharmacokinetics.

Silence Therapeutics plc announced that Company management will participate in the following investor conferences and invited investors to participate by webcast.

Apollo Therapeutics, a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, announces the close of $226.5 million in a Series C financing led by lead investor Patient Square Capital.

KSQ Therapeutics, Inc. and CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, announced a strategic collaboration to expedite the development of KSQ’s two lead engineered tumor-infiltrating lymphocyte programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical studies for the treatment of solid tumors.

Bausch + Lomb Corporation, a leading global eye health company dedicated to helping people see better to live better, announced 13 podium and poster presentations during the European Society of Cataract and Refractive Surgery annual meeting, which will take place in Vienna Sept. 8-12, 2023.

Moderna, Inc. announced that clinical trial data from its research assay confirm its updated COVID-19 vaccine, which is pending approval by the U.S. Food and Drug Administration for the fall 2023 vaccination season, generates an 8.7-fold increase in neutralizing antibodies in humans against BA.2.86, a variant under monitoring.

SIGA Technologies, Inc., a commercial-stage pharmaceutical company focused on the health security market, announced that Dr. Jay K. Varma has joined SIGA as Executive Vice President and Chief Medical Officer.